Caredx (CDNA) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $4.13B
- As of Nov 13, 2026
- P/E
- 32.00x
- Trailing twelve months
- P/B
- 8.84x
- Latest reported equity
- P/S
- 8.31x
- Trailing twelve months
- ROE
- 27.6%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $4.13B
- As of Nov 13, 2026
- P/E
- 32.00x
- Trailing twelve months
- P/B
- 8.84x
- Latest reported equity
- P/S
- 8.31x
- Trailing twelve months
- ROE
- 27.6%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
32.00x
P/B
8.84x
P/S
8.31x
Earnings and dividend metrics▾
Earnings
EPS
$2.43
Earnings per share
BPS
$8.81
Book value per share
ROE
27.6%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $2.43 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $8.81 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 27.6%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 39.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $100M+39.0%
$83M
Jul–Sep '24
$100M
Jul–Sep '25
$139M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 29, 2026.
- Earnings per share increased 1,066.7% from the same quarter a year earlier.
- Revenue increased 39.0% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased 850.0% from the same quarter a year earlier.
Filed Oct 29, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Novack Jeffrey AdamSecretary and General Counsel · Nov 10, 2026Open-market sale4,096 shares · $332KAvg. price $81.1258
Show 3 price lots
- 2,996 shares × $80.4694$241K
- 900 shares × $83.3278$75K
- 200 shares × $81.05$16K
- Bickerstaff GeorgeDirector · Nov 10, 2026Option exercise15,000 shares · $221KAvg. price $14.74149,061 shares held after
- Novack Jeffrey AdamSecretary and General Counsel · Nov 6, 2026Shares withheld for taxes1,505 shares · $118KAvg. price $78.56100,700 shares held after
- Kennedy KeithCFO & COO · Nov 5, 2026Open-market sale61,961 shares · $4.8MAvg. price $77.8185
Show 8 price lots
- 28,256 shares × $76.5485$2.2M
- 12,380 shares × $77.4184$958K
- 7,415 shares × $79.4853$589K
- 6,897 shares × $78.5875$542K
- 3,403 shares × $80.3783$274K
- 2,710 shares × $81.4041$221K
- 600 shares × $83.6$50K
- 300 shares × $82.0767$25K
- Kennedy KeithCFO & COO · Nov 5, 2026Option exercise52,422 shares · $1.5MAvg. price $29.43261,108 shares held after
- Cohen Fred EDirector · Nov 3, 2026Gift25,000 shares · $0Avg. price $0140,060 shares held after
- Novack Jeffrey AdamSecretary and General Counsel · Nov 1, 2026Shares withheld for taxes2,873 shares · $247KAvg. price $85.88102,205 shares held after
- Goldberg MichaelDirector · Oct 2, 2026Grant or award588 shares · $0Avg. price $062,326 shares held after
- Hanna John Walter JRPresident and CEO · Oct 1, 2026Shares withheld for taxes8,511 shares · $564KAvg. price $66.23644,937 shares held after
- Kennedy KeithCFO & COO · Oct 1, 2026Shares withheld for taxes3,018 shares · $200KAvg. price $66.23208,686 shares held after
- Meng JessicaChief Commercial Officer · Oct 1, 2026Shares withheld for taxes2,619 shares · $173KAvg. price $66.23158,980 shares held after
- Novack Jeffrey AdamSecretary and General Counsel · Oct 1, 2026Shares withheld for taxes997 shares · $66KAvg. price $66.23105,078 shares held after
- Kennedy KeithCFO & COO · Sep 12, 2026Shares withheld for taxes8,220 shares · $430KAvg. price $52.37211,704 shares held after
- Meng JessicaChief Commercial Officer · Sep 12, 2026Shares withheld for taxes6,688 shares · $350KAvg. price $52.37161,599 shares held after
- Bickerstaff GeorgeDirector · Aug 5, 2026Open-market sale20,000 shares · $926KAvg. price $46.285134,061 shares held after
- Novack Jeffrey AdamSecretary and General Counsel · Aug 5, 2026Open-market sale2,688 shares · $124KAvg. price $46.261
Show 2 price lots
- 2,188 shares × $46.1492$101K
- 500 shares × $46.75$23K
- Goldberg MichaelDirector · Aug 4, 2026Open-market sale44,700 shares · $2.1MAvg. price $47.058161,738 shares held after
- COURNOYER CHRISTINEDirector · Aug 4, 2026Open-market sale16,000 shares · $751KAvg. price $46.935842,943 shares held after
- Novack Jeffrey AdamSecretary and General Counsel · Aug 1, 2026Shares withheld for taxes2,872 shares · $137KAvg. price $47.85108,763 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Caredx (CDNA) stock information
NASDAQ
Caredx (CDNA) is listed on NASDAQ. Its market capitalization is about $4.1B. On trailing-twelve-month earnings the P/E ratio is 32, and the P/B ratio is 8.84. Return on equity is 27.6%. These figures are computed in-house from official filings and are reference information only.
Caredx — frequently asked questions
- What is the P/E ratio of Caredx (CDNA)?
- On a trailing-twelve-month basis, CDNA trades at a P/E ratio of 32. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Caredx?
- CDNA has a market capitalization of about $4.1B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.